AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8830061
Drug: Nefazodone, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone, 200 mg twice daily + Triazolam, 0.25 mg
Trial: 8830061
Drug: Alprazolam, 1
RxNorm normalized name: Alprazolam, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam, 1 mg twice daily
Trial: 8830061
Drug: Alprazolam, 1
RxNorm normalized name: Alprazolam, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam, 1 mg twice daily + Nefazodone, 200 mg
Trial: 8830061
Drug: Lorazepam, 2
RxNorm normalized name: Lorazepam, 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam, 2 mg twice daily
Trial: 7466726
Drug: Intrapleural BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural BCG treatment followed by scarifications (BCG-B)
Trial: 28586918
Drug: Nebulized Hypertonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized Hypertonic Saline (HS) 3% - 4 mL, two 20-minute treatments
Trial: 28586918
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (NS) 0.9% - 4 mL, two 20-minute treatments
Trial: 21736837
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil enriched with 45 μg MK-7
Trial: 21736837
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil enriched with 90 μg MK-7
Trial: 16766337
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral itraconazole pulse therapy for 3 months (200 mg x 2/day for 1 week/month) followed by an additional single course (200 mg/day for 7 days) after 3 months.
Trial: 16766337
Drug: Modified itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified itraconazole pulse therapy (6-week interval) x3 followed by an additional single course (200 mg x 2/day for 7 days) after 3 months.
Trial: 11738071
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (100 mg/kg)
Trial: 7911009
Drug: Acrivastine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acrivastine (8 mg)
Trial: 24817035
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg)
Trial: 26905469
Drug: Antenatal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroid administration before elective caesarean section at term
Trial: 21219436
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus insulin injection
Trial: 21303634
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous insulin infusion
Trial: 16835281
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg/month)
Trial: 12830733
Drug: Novel targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel targeted therapies
Trial: 12830733
Drug: Nonspecific cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific cytotoxic chemotherapeutic agents
Trial: 9124056
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol (0.1 mg/kg per dose, four times a day)
Trial: 9124056
Drug: MDI salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDI salbutamol (200 micrograms per dose, every 3 h)
Trial: 9124056
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no bronchodilator therapy)
Trial: 7908144
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate nasal spray (BDP)
Trial: 7908144
Drug: Placebo/azelastine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/azelastine treatment
Trial: 3223752
Drug: Pivmecillinam (perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam (perioperative treatment from the evening before the operation to the day after removal of the catheter)
Trial: 3223752
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no perioperative treatment)
Trial: 25308771
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride 50 mg/day for 6 weeks
Trial: 25910064
Drug: Low-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume preparation (15 mg bisacodyl plus 2 L polyethylene glycol [PEG] solution)
Trial: 25910064
Drug: High-volume preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume preparation (4 L PEG)
Trial: 12881209
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (1,000 mg) and vitamin E (800 IU) daily for 6 months
Trial: 1914560
Drug: Fluid gain
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid gain less than 1 L by 36 hours
Trial: 1914560
Drug: Fluid gain
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid gain greater than 1 L by 36 hours
Trial: 1914560
Drug: Median duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median duration of days on the ventilator, ICU days, and days of hospitalization for less than 1 L fluid gain
Trial: 6114721
Drug: Follow-up interviews
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up interviews at one and six months after treatment
Trial: 30501950
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Ticagrelor 90 mg twice per day
Trial: 30501950
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Clopidogrel 75 mg once per day
Trial: 21145828
Drug: High-dose ursodesoxycholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ursodesoxycholic acid (HD-UDCA) 28-35 mg/kg per day
Trial: 21145828
Drug: High-dose ursodesoxycholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ursodesoxycholic acid (HD-UDCA)
Trial: 15088420
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg, oral single dose)
Trial: 15088420
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg, oral single dose)
Trial: 8201382
Drug: 131I‐mAbF19 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I‐mAbF19 administered intravenously
Trial: 28899715
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D) supplementation (100,000 loading dose followed by 4000 IU daily for 16 weeks)
Trial: 23146065
Drug: Topical acetyl
RxNorm normalized name: Acetyl sulfisoxazole
DrugBank: Acetyl sulfisoxazole (DB14033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acetyl hexapeptide-8 (AH8)
Trial: 12635780
Drug: Palatal plate
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal plate therapy (PPG)
Trial: 1825278
Drug: Effective nursing
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective nursing intervention, antifungal medication, and a moisture barrier ointment
Trial: 6210180
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dimetophrine tablets
Trial: 6210180
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg midodrine tablets
Trial: 30880286
Drug: Polysomnographic titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysomnographic titration (PSG)
Trial: 30880286
Drug: Control (daytime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (daytime titration followed by sham PSG)
Trial: 22948494
Drug: Rectal/nasopharyngeal trumpet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal/nasopharyngeal trumpet
Trial: 21930596
Drug: IH with
RxNorm normalized name: trenbolone acetate 80 mg / estradiol 8 mg / tylosin tartrate 29 mg SUBCUTANEOUS IMPLANT [Component TE-IH With Tylan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IH with placebo medication
Trial: 20625082
Drug: IH with
RxNorm normalized name: trenbolone acetate 80 mg / estradiol 8 mg / tylosin tartrate 29 mg SUBCUTANEOUS IMPLANT [Component TE-IH With Tylan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IH with losartan (type I angiotensin II receptor antagonist)
Trial: 18346622
Drug: Reflexology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatment (40 min, once per week for six weeks)
Trial: 18346622
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (40 min, once per week for six weeks)
Trial: 18346622
Drug: Reflexology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatment
Trial: 15981065
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation with polyethylene glycol (PEG group)
Trial: 12521651
Drug: Continuous group
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous group (168 days without a pill-free interval)
Trial: 2694742
Drug: Clindamycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (single preoperative dose)
Trial: 786668
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine (100 mg)
Trial: 786668
Drug: Oral meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meperidine (150 mg)
Trial: 786668
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of intramuscular dose (mg/kg)
Trial: 28579415
Drug: Elagolix alone
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix alone (100 mg BID, 200 mg BID, 300 mg BID, 400 mg QD, 600 mg QD)
Trial: 28579415
Drug: Elagolix with
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix with add-back therapy (200 mg BID plus continuous low-dose E2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E2 1 mg continuously and cyclical P 200 mg)
Trial: 25196993
Drug: Blosozumab 270
RxNorm normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blosozumab 270 mg every 2 weeks (Q2W)
Trial: 25196993
Drug: Blosozumab 180
RxNorm normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blosozumab 180 mg every 2 weeks (Q2W)
Trial: 23820652
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve blockade in addition to intrarectal lidocaine gel
Trial: 19752608
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel
Trial: 19032723
Drug: Ibudilast 30
RxNorm normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Ibudilast 30 mg single administration followed by 30 mg b.i.d. for 14 days
Trial: 7629954
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg daily)
Trial: 11281167
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid emulsion (1.6 ml)
Trial: 11281167
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid emulsion (3.2 ml)
Trial: 11281167
Drug: Control emulsion
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control emulsion (0 ml oleic acid)
Trial: 11281167
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid treatment
Trial: 8140906
Drug: Mianserin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (daily dose 20-60 mg)
Trial: 2849539
Drug: NaHCO3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NaHCO3 treatment (2.9 mmol of NaHCO3.kg‐1 body weight)
Trial: 2849539
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (17 mmol of NaCl)
Trial: 2849539
Drug: No-drink treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drink treatment
Trial: 560645
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tyramine
Trial: 30178577
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral aspirin
Trial: 27846743
Drug: Enalapril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (ACE inhibitor, 5 mg od)
Trial: 27846743
Drug: Candesartan (AT1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (AT1R antagonist, 8 mg od)
Trial: 19365151
Drug: ABIO-08/01 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABIO-08/01 (10 mg)
Trial: 19365151
Drug: ABIO-08/01 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABIO-08/01 (20 mg)
Trial: 19365151
Drug: ABIO-08/01 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABIO-08/01 (40 mg)
Trial: 17498886
Drug: Goserelin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin and flutamide for 2 months before and during radiation therapy (RT) +/− 24 months of goserelin (long-term androgen deprivation plus radiation [LTAD-RT])
Trial: 15161117
Drug: rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rofecoxib 50 mg once daily
Trial: 7626858
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose chemotherapy
Trial: 7905523
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine (1000 mg every 8 h and 100 mg every 8 h, respectively)
Trial: 7905523
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine
Trial: 2594133
Drug: Intraventricular injection
RxNorm normalized name: Brineura 150 MG in 5 mL Intraventricular Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraventricular injection of morphine
Trial: 2594133
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of morphine
Trial: 31670776
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block (subcutaneous)
Trial: 30951210
Drug: Achieving at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieving at least a 1-level reduction in WHO risk drinking levels by the end of treatment
Trial: 30951210
Drug: Achieving at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieving at least a 2-level reduction in WHO risk drinking levels by the end of treatment
Trial: 29279933
Drug: Cefazolin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1000 mg intravenous preoperative dose)
Trial: 29279933
Drug: Saline (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% sodium chloride intravenous preoperative dose)
Trial: 25925742
Drug: Gold standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard programme for alcohol cessation intervention, including structured patient education, weekly intervention meetings, thiamine and B-vitamins, alcohol withdrawal prophylaxis, and disulfiram for abstinence support.
Trial: 24393553
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg linagliptin once daily
Trial: 24393553
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg linagliptin
Trial: 20680276
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (closed reduction followed by fragment excision)
Trial: 20680276
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (closed reduction)
Trial: 16374142
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day after 12 months
Trial: 1410747
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of mepivacaine 2% at craniostate fixation points
Trial: 2866291
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2 litres of 0.9% saline over 1 hour)
Trial: 29172800
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire (Group A)
Trial: 29172800
Drug: GP-administered questionnaire
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP-administered questionnaire (Group B)
Trial: 28304291
Drug: Insulin Resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Resistance (top HOMA-IR quartile)
Trial: 25899029
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion (0.15 mmol/kg body weight/h)
Trial: 25899029
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no sodium bicarbonate infusion)
Trial: 20184225
Drug: Triflusal capsules
RxNorm normalized name: triflusal
DrugBank: Triflusal (DB08814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal capsules (300 mg x 2)
Trial: 15893540
Drug: Marimastat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat (5 mg)
Trial: 12849799
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch (group 1 and group 2)
Trial: 1768561
Drug: Levodopa (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (125 mg, three oral doses at 2-hour intervals)
Trial: 1768561
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of soluble paracetamol with levodopa
Trial: 1768561
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of radiolabelled DTPA with levodopa
Trial: 24326003
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg/day
Trial: 25455721
Drug: 100,000 units
RxNorm normalized name: nystatin 100,000 units vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100,000 units oral vitamin D3 every 2 months for 6 months
Trial: 22773397
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefazolin systemically 10 minutes before tourniquet inflation
Trial: 22773397
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefazolin intraosseously in 200 mL of normal saline after tourniquet inflation
Trial: 12875066
Drug: Anti-epilepsy capsules
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-epilepsy capsules
Trial: 10868558
Drug: Loratadine syrup
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine syrup (5 mg, 1 mg/mL)
Trial: 3080865
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (IV)
Trial: 29114936
Drug: Simple training
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple training comprising four basic, single‐molecule substances
Trial: 27068399
Drug: Atazanavir/ritonavir (300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (300/100 mg)